PAREXEL Simplifies Access to Knowledge

September 10, 2018
A new report by the Economist Intelligence Unit (EIU) and commissioned by PAREXEL International Corporation reveals that new innovations in drug development have a positive impact on clinical trial timelines, likelihood of market launch, and inclusion on selected payer formularies.
Previous Video
Sy Pretorius, M.D., on PAREXEL's Patient Innovation Center
Sy Pretorius, M.D., on PAREXEL's Patient Innovation Center

Watch Sy Pretorius, M.D., PAREXEL’s Senior Vice President and Chief Medical & Scientific Officer discuss ho...

Next Video
Michelle Hoiseth on the Importance of Real-World Data
Michelle Hoiseth on the Importance of Real-World Data

Real-World Data provides important opportunities for the drug development industry. Michelle Hoiseth, PAREX...